New hope for ALS: phase 3 trial of masitinib launches
NCT ID NCT07174492
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This phase 3 trial tests whether adding masitinib to standard ALS treatment (riluzole) can slow the loss of physical function better than placebo. About 412 adults with ALS will take masitinib or a dummy pill for 48 weeks. The main goal is to measure changes in daily abilities and breathing using a standard disability scale.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aiginition Hospital
Athens, Greece
Contact
Conditions
Explore the condition pages connected to this study.